Cargando…
Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
An 82-year-old man with a recurrence of pulmonary pleomorphic carcinoma was treated with pembrolizumab. He achieved partial response after three cycles of pembrolizumab. However, he developed febrile neutropenia. A bone marrow aspiration sample revealed a decrease of mature neutrophils, and anti-neu...
Autores principales: | Tozuka, Takehiro, Sugano, Teppei, Noro, Rintaro, Takano, Natsuki, Hisakane, Kakeru, Takahashi, Satoshi, Tanaka, Toru, Kashiwada, Takeru, Takeuchi, Susumu, Kunugi, Shinobu, Minegishi, Yuji, Saito, Yoshinobu, Kubota, Kaoru, Seike, Masahiro, Gemma, Akihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196766/ https://www.ncbi.nlm.nih.gov/pubmed/30364514 http://dx.doi.org/10.1093/omcr/omy094 |
Ejemplares similares
-
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
por: Tozuka, Takehiro, et al.
Publicado: (2018) -
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018) -
Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
por: Sugano, Teppei, et al.
Publicado: (2020) -
Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
por: Hisakane, Kakeru, et al.
Publicado: (2021) -
Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)